Youth Substance Use in the US: 2022 Report

Jan.03.2023
Youth Substance Use in the US: 2022 Report
American teenage drug use remains stable after a sharp decline in 2021 due to COVID-19 school closures and social distancing.

According to the latest report from a monitoring and survey agency in the United States, which assesses illegal substance use and associated attitudes in 8th, 10th, and 12th grade students, the proportion of American teenagers using illegal substances remained relatively stable in 2022 following a significant decrease in 2021. Almost all substances reported a decrease in usage from 2020 to 2021, likely due to the COVID-19 pandemic and related changes such as school closures and social distancing.


By 2022, it is expected that all grade levels mentioned in the report will maintain or demonstrate a substantial decrease in the use of illegal substances within the past year. Currently, 11% of eighth graders, 21.5% of tenth graders, and 32.6% of twelfth graders reported using illegal drugs within the past year.


The Monitoring the Future survey is conducted annually by researchers from the University of Michigan in Ann Arbor and is funded by the National Institute on Drug Abuse, which is a part of the National Institutes of Health.


A recent study found that alcohol, nicotine e-cigarettes, and marijuana are the most commonly reported substances used by teenagers in the past year, with levels remaining relatively stable compared to 2021. While there were some substances that showed an increase in reported usage from the previous year, the majority of reported usage levels remained the same or lower than pre-pandemic levels in 2020. When compared to levels observed in 2021, data reported in 2022 shows:


Nicotine electronic cigarettes remain stable among all three grades, with 12% of eighth graders, 20.5% of tenth graders, and 27.3% of twelfth graders reporting the use of nicotine in the past year.


The results of the survey indicate that the prevalence of cannabis use among students in grades eight, ten, and twelve has remained stable. 8.3% of eighth-grade students, 19.5% of tenth-grade students, and 30.7% of twelfth-grade students reported using cannabis in the past year. It is noteworthy that 6% of eighth-grade students, 15% of tenth-grade students, and 20.6% of twelfth-grade students reported smoking cannabis in the past year, indicating that the prevalence among eighth and twelfth-grade students has remained stable while there has been a slight increase in reported cannabis use among tenth-grade students, although the 2022 figures for tenth-graders are significantly lower than pre-pandemic levels.


The rate of alcohol consumption among eighth and tenth grade students remained steady (with 15.2% and 31.3% respectively reporting drinking in the past year), but the rate among twelfth grade students has returned to pre-pandemic levels (with 51.9% of twelfth graders reporting drinking in the past year in 2022).


According to a survey, the use of any illegal drugs other than marijuana has remained stable among all three grades surveyed. 4.9% of eighth-grade students, 5.7% of tenth-grade students, and 8% of twelfth-grade students reported using any illegal drugs other than marijuana in the past year. These data are based on long-term trends that show relatively low and stable levels of illicit substance use among adolescents, including the use of cocaine, heroin, amphetamines, and non-medical use of prescription drugs over the past year.


During the period of 2021 to 2022, there was a slight increase in the number of 12th grade students using anesthesia other than heroin, including Vicodin, OxyContin and Percocet (1.7% of 12th grade students reported using these drugs in the past year). This level remained consistent with pre-pandemic observations in 2019 and 2020 (2.7% and 2.1% respectively).



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs data showed that illegal cigarettes and vape products seized during the first seven months of 2026 were valued at about PHP11.68 billion, exceeding the PHP2.516 billion recorded for the full year of 2025. The figures were disclosed by a Bureau of Customs official during a House Committee on Ways and Means hearing on tobacco excise tax reforms. Vape-related seizures were valued at about PHP1.65 billion, with most cases recorded at the Manila International Container Port. Customs officials said enforcement against illicit tobacco trade would continue.
Aug.26
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
AIR’s first half-year results as a listed company offer a new test of how far a traditional hookah business can transform. H1 2026 revenue rose 3.7%, even as Flavored Shisha Molasses shipments fell 9%, with pricing and mix supporting growth. Traditional shisha still generates almost all revenue, while OOKA, Crown Switch, Greentank and U.S. regulatory spending point to accelerating diversification. The next test is whether those investments can become a second business of meaningful scale and profitability.
Capital Markets
Aug.21
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia's federal government introduced a new illicit tobacco enforcement bill on September 10 that would strengthen evidentiary presumptions, representative sampling, seizure and forfeiture procedures, proceeds-of-crime powers and obligations for customs and logistics operators. The proposal follows the Combatting Illicit Tobacco Act 2026, which took effect in August and increased penalties while expanding investigative and asset-recovery tools. Together, the reforms extend Australia's crackdown from tougher criminal sanctions into import, logistics and evidentiary enforcement.
Sep.14
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13